Salivary proteomics in monitoring the therapeutic response of canine oral melanoma

xlomafota13 shared this article with you from Inoreader Salivary proteomics in monitoring the therapeutic response of canine oral melanoma Via Head and neck cancers by Sekkarin Ploypetch, Sittiruk Roytrakul, Janthima Jaresitthikunchai, Narumon Phaonakrop, Patharakrit Teewasutrakul, Anudep Rungsipipat, Gunnaporn Suriyaphol Saliva biomarkers are suitable for monitoring the therapeutic response of canine oral melanoma (COM), because saliva directly contacts the tumor, and saliva collection is non-invasive, convenient and cost effective. The present study aimed to investigate novel biomarkers from the salivary proteome of COM treated with surgery and a chemotherapy drug, carboplatin, 1–6 times, using a liquid chromatography–tandem mass spectrometry approach. The expression of a potential salivary biomarker, ubiquitin D (UBD), was observed and verified by western blot analysis. A significantly increased ratio of free UBD (fUBD) to conjugated UBD (cUBD) was shown in the pre-surgery stage (PreS) in OM dogs with short-term survival (STS) (less than 12 months after surgery) compared with that with long-term survival (more than 12 months after surgery). In dogs with STS, the ratio was also shown to be augmented in PreS compared with that after surgery, followed by treatment with carboplatin twice, 4 and 5 t imes [After treatment (AT)2, AT4 and AT5]. In addition, the expression of fUBD was enhanced in PreS compared with that of AT2 in the STS group. In conclusion, this study revealed that a ratio of fUBD to cUBD in PreS was plausibly shown to be a potential prognostic biomarker for survival in dogs with OM. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.